<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title>Frontiers in Physiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Physiol.</abbrev-journal-title>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphys.2019.00799</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Oxidative Stress and Hemostatic Parameters in Patients With Nephrolithiasis Before and After Ureteroscopic Lithotripsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wo&#x017A;niak</surname> <given-names>Pawe&#x0142;</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kontek</surname> <given-names>Bogdan</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Skalski</surname> <given-names>Bartosz</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/537231/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kr&#x00F3;l</surname> <given-names>Anna</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>R&#x00F3;&#x017C;a&#x0144;ski</surname> <given-names>Waldemar</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Olas</surname> <given-names>Beata</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/486786/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>2nd Department of Urology, Medical University of &#x0141;&#x00F3;d&#x017A;</institution>, <addr-line>&#x0141;&#x00F3;d&#x017A;</addr-line>, <country>Poland</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of &#x0141;&#x00F3;d&#x017A;</institution>, <addr-line>&#x0141;&#x00F3;d&#x017A;</addr-line>, <country>Poland</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Bellamkonda K. Kishore, University of Utah Health Care, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Laith Farah Al-rabadi, University of Utah Hospital, United States; Alan Pao, Stanford University, United States</p></fn>
<corresp id="c001">&#x002A;Correspondence: Beata Olas, <email>beata.olas@biol.uni.lodz.pl</email></corresp>
<fn fn-type="other" id="fn002"><p>This article was submitted to Renal and Epithelial Physiology, a section of the journal Frontiers in Physiology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>799</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>02</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>06</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2019 Wo&#x017A;niak, Kontek, Skalski, Kr&#x00F3;l, R&#x00F3;&#x017C;a&#x0144;ski and Olas.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Wo&#x017A;niak, Kontek, Skalski, Kr&#x00F3;l, R&#x00F3;&#x017C;a&#x0144;ski and Olas</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<sec><title>Purpose</title>
<p>In patients with nephrolithiasis, oxidative stress, especially lipid peroxidation is observed. Moreover, various invasive methods [including extracorporeal shock wave lithotripsy (ESWL)] for treatment of nephrolithiasis may induce not only the oxidative stress, but they may modulate hemostasis. The study was aimed to evaluate the oxidative damages of lipids and proteins in patients with nephrolithiasis (before and after ureteroscopic lithotripsy &#x2013; URSL). The aim of the present study was also determine selected parameters of hemostasis in these patients.</p>
</sec>
<sec><title>Methods</title>
<p>56 patients with nephrolithiasis and 49 healthy participants were included: 30 men and 26 women (for patient group); 27 men and 22 women (for healthy group). We measured the level of selected typical two biomarkers of oxidative modification of lipids [such as the production of thiobarbituric acid reactive substances (TBARS) and isoprostane concentration (8-isoPGF<sub>2&#x03B1;</sub>)] and two biomarkers of oxidative damages of proteins (carbonylation and the level of thiol groups) in patients with nephrolithiasis (before and after URSL). The following parameters of hemostasis were measured: blood platelet count, the level of fibrinogen and D-dimer, and coagulation times (the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) of plasma).</p>
</sec>
<sec><title>Results</title>
<p>Different levels of plasma lipid peroxidation were observed in patients with nephrolithiasis before URSL and after URSL. However, no such difference in the level of oxidative damage to plasma proteins was observed. In addition, the tested hemostasis parameters were not influenced by the presence of nephrolithiasis, nor by treatment with URSL.</p>
</sec>
<sec><title>Conclusion</title>
<p>We suggest URSL does not induce the oxidative modifications of plasma proteins and does not change hemostatic parameters in patients with nephrolithiasis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>hemostasis</kwd>
<kwd>nephrolithiasis</kwd>
<kwd>oxidative stress</kwd>
<kwd>ureteroscopic lithotripsy</kwd>
<kwd>extracorporeal shock wave lithotripsy</kwd>
</kwd-group>
<counts>
<fig-count count="9"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="25"/>
<page-count count="8"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Oxidative stress causes damage to different biomolecules &#x2013; lipids, proteins and DNA. Moreover, oxidative stress may induce changes elements of hemostasis (including coagulation process and blood platelet activation) in various diseases. In recent years, various studies demonstrated that oxidative stress exists in patients with nephrolithiasis, however, the mechanism(s) of this process is not well known. It has been previously shown that especially lipid peroxidation [measured by different biomarkers: 8-isoprostaglandin F<sub>2</sub> (8-isoPGF<sub>2&#x03B1;</sub>) and thiobarbituric acid reactive substances (TBARS)] exists in these patients. Increase of lipid peroxidation was demonstrated in different biological materials (serum, plasma, erythrocytes, and urine) obtained from patients with nephrolithiasis (<xref ref-type="bibr" rid="B11">Khan, 2005</xref>, <xref ref-type="bibr" rid="B12">2012</xref>, <xref ref-type="bibr" rid="B13">2013a</xref>,<xref ref-type="bibr" rid="B14">b</xref>, <xref ref-type="bibr" rid="B15">2014</xref>; <xref ref-type="bibr" rid="B4">Boonla et al., 2007</xref>; <xref ref-type="bibr" rid="B17">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="B5">Ceban et al., 2016</xref>). In addition, various invasive methods [including extracorporeal shock wave lithotripsy (ESWL)] for treatment of nephrolithiasis may also induce the oxidative stress (<xref ref-type="bibr" rid="B8">Gecit et al., 2012</xref>; <xref ref-type="bibr" rid="B6">Garca et al., 2014</xref>; <xref ref-type="bibr" rid="B24">Wozniak et al., 2017</xref>, <xref ref-type="bibr" rid="B25">2018</xref>) and modulate hemostasis (<xref ref-type="bibr" rid="B24">Wozniak et al., 2017</xref>). Modulation of hemostasis was observed 30&#x2013;240 min after shock wave lithotripsy (SWL) (<xref ref-type="bibr" rid="B10">Hughes et al., 2015</xref>) and the day after ESWL (<xref ref-type="bibr" rid="B24">Wozniak et al., 2017</xref>).</p>
<p>Ureteroscopic lithotripsy (URSL) is one of the most common operations in urology. Moreover, it is and important that is an effective and safe method for managing ureteral stones (<xref ref-type="bibr" rid="B20">Seitz et al., 2007</xref>; <xref ref-type="bibr" rid="B21">Tao et al., 2015</xref>). Complications occur in less than 0.1% of cases (<xref ref-type="bibr" rid="B19">Nuttall et al., 2010</xref>). However, the effect of URSL on parameters of oxidative stress and hemostasis in patients with nephrolithiasis has not been studied yet. Thus, the main objective of our experiments was to examine the level of selected typical two biomarkers of oxidative modification of lipids (such as the production of TBARS and isoprostane concentration) and two biomarkers of oxidative damages of proteins (carbonylation and the level of thiol groups) in patients with nephrolithiasis (before and after URSL). Moreover, the aim of the present study was also determine selected parameters of hemostasis (blood platelet count, the level of fibrinogen and D-dimer, and coagulation times (the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) of plasma) in these patients.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Patients and Samples</title>
<p>The blood samples were collected from 56 patients (30 men and 26 women) whom had been referred to the 2nd Department of Urology, Medical University of &#x0141;&#x00F3;d&#x017A;, Poland, for URSL. The exclusion criteria were as follows: the presence of urinary tract infection, other inflammatory or malignant disease, diabetes mellitus, history of heart disease, or chronic kidney disease. Before URSL anatomy of the kidney and excretory path for all patients were investigated by intravenous urography, and no anomalies were found.</p>
<p>A group of 49 healthy individuals (27 men and 22 women) were collected from the hospital from routine controls of health and used as control. They were non-related men and women, that have never been diagnosed with nephrolithiasis or chronic disease and were randomly selected and frequency matched to the cases on age.</p>
<p>The blood and urine samples were collected from the patients before URSL, and 1 day after URSL. The blood samples and the urine samples were taken from patients and healthy participants keeping a balanced diet (meat and vegetables), with similar socio-economic background, using no antioxidant supplementation and any medications (f.e. anti-platelet drugs or anti-inflammatory agents).</p>
<p>Erythrocytes were separated from plasma by centrifugation (2800 &#x00D7; <italic>g</italic> for 10 min). Concentration of hemoglobin was determined by the cyanohemoglobin method using Drabkin&#x2019;s reagent. Participants provided also first morning void urine samples (50&#x2013;100 ml), which was kept on ice and processed within 4 h. Plasma samples obtained from the participants were stored at &#x2212;80&#x00B0;C within 2 h of removal.</p>
<p>The protocol was passed by the Committee for Research on Human Subjects of the Medical University of &#x0141;&#x00F3;d&#x017A; RNN/101/13/KE. The protocol was passed by the Committee for Research on Human Subjects of the Medical University of &#x0141;&#x00F3;d&#x017A; RNN/101/13/KE. The first, participants provided verbal consent to the researchers, and later participants provided written the documents. Authors had access to identifying participant information.</p>
</sec>
<sec><title>Parameters of Oxidative Stress</title>
<sec><title>Measurement of Lipid Peroxidation &#x2013; The Level of 8-isoPGF<sub>2&#x03B1;</sub></title>
<p>The level of 8-isoPGF<sub>2&#x03B1;</sub> was estimated in urine samples from control subjects and from patients using an immunoassay kit (Cayman Chemical) according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec><title>Measurement of Lipid Peroxidation &#x2013; The Level of TBARS</title>
<p>Samples of plasma or erythrocytes were transferred to an equal volume of cold 20% (v/v) trichloroacetic acid in 0.6 M HCl and centrifuged at 1200 &#x00D7; <italic>g</italic> for 15 min. One volume of clear supernatant was mixed with 0.2 volume of 0.12 M thiobarbituric acid in 0.26 M Tris (pH 7.0) immersed in a boiling water bath for 15 min. and then absorbance was measured at 535 nm (the SPECTROstar Nano Microplate Reader &#x2013; BMG LABTECH Germany) (<xref ref-type="bibr" rid="B22">Wachowicz, 1984</xref>; <xref ref-type="bibr" rid="B3">Bartosz, 2008</xref>). The TBARS concentration was calculated using the molar extinction coefficient (&#x03B5; = 156,000 M<sup>&#x2212;1</sup>cm<sup>&#x2212;1</sup>).</p>
</sec>
<sec><title>Measurement of Protein Carbonylation</title>
<p>The detection of carbonyl groups in proteins was carried out according to <xref ref-type="bibr" rid="B16">Levine et al. (1990)</xref> and <xref ref-type="bibr" rid="B3">Bartosz (2008)</xref>. The carbonyl group concentration was calculated using a molar extinction coefficient (&#x03B5; = 22,000 M<sup>&#x2212;1</sup>cm<sup>&#x2212;1</sup>), and the level of carbonyl groups was expressed as nmol carbonyl groups/mg of protein. Carbonyl content was determined by taking the SPECTROstar Nano Microplate Reader &#x2013; BMG LABTECH Germany.</p>
</sec>
<sec><title>Measurement of the Level of Thiol Groups</title>
<p>The thiol group content was measured spectrophotometrically (the SPECTROstar Nano Microplate Reader &#x2013; BMG LABTECH Germany) by absorbance at 412 nm with Ellman&#x2019;s reagent: 5,5&#x2032;-dithio-bis-(2-nitrobenzoic acid). The thiol group concentration was calculated using a molar extinction coefficient (&#x03B5; = 13,600 M<sup>&#x2212;1</sup>cm<sup>&#x2212;1</sup>) (<xref ref-type="bibr" rid="B1">Ando and Steiner, 1973a</xref>,<xref ref-type="bibr" rid="B2">b</xref>; <xref ref-type="bibr" rid="B3">Bartosz, 2008</xref>). The level of thiol groups was expressed as nmol thiol groups/mg of plasma protein.</p>
</sec>
</sec>
<sec><title>Parameters of Hemostasis</title>
<sec><title>The Measurement of Prothrombin Time</title>
<p>The PT (seconds) was determined coagulometrically (BCS XP Healthcare Diagnostics Siemens, Germany) in citrated samples.</p>
</sec>
<sec><title>The Measurement of Thrombin Time</title>
<p>The TT (seconds) was determined coagulometrically (BCS XP Healthcare Diagnostics Siemens, Germany) in citrated samples.</p>
</sec>
<sec><title>The Measurement of APTT</title>
<p>The APTT (seconds) was determined coagulometrically (BCS XP Healthcare Diagnostics Siemens, Germany) in citrated samples.</p>
</sec>
<sec><title>The Measurement of Blood Platelet Concentration</title>
<p>Blood platelet count was performed using an automated cell counter (Sysmex XN-2000, Sysmex, Japan) in citrated samples. The platelets were measured in units &#x00D7; 10<sup>9</sup>/l.</p>
</sec>
<sec><title>The Measurement of Fibrinogen</title>
<p>Fibrinogen (g/l) concentration (in citrated samples) was measured using an analyzer (BCS XP Healthcare Diagnostics Siemens, Germany).</p>
</sec>
<sec><title>The Measurement of D-Dimer</title>
<p>D-dimer (ng/ml) concentration was determined by an analyser (BCS XP Healthcare Diagnostics Siemens, Germany) in citrated samples.</p>
</sec>
</sec>
<sec><title>Statistical Analysis</title>
<p>The statistical analysis was done by several tests. All the values in this study were expressed as mean &#x00B1; SD. In order to eliminate uncertain data, Q-Dixon test was performed. Since levels of biomarkers of oxidative stress in studied material did not show normal distribution (Kolmogorov&#x2013;Smirnov test) the non-parametrical statistical test (Mann-Whitney <italic>U</italic> test) was applied. Reported <italic>p</italic>-values were two-sided. All analyses were completed using STATISTICA 12.</p>
</sec>
</sec>
<sec><title>Results</title>
<p>As demonstrated on <xref ref-type="fig" rid="F1">Figure 1</xref>, the TBARS level in plasma was significantly increase in patients with nephrolithiasis (before URSL) than in control. In plasma samples from patients with nephrolithiasis (before URSL), the level of TBARS was increase by about 116% compare to control group (<xref ref-type="fig" rid="F1">Figure 1</xref>). The concentration of TBARS in plasma from patients with nephrolithiasis (after URSL) was also higher than in patients with nephrolithiasis (before URSL) and higher than in healthy volunteers (<xref ref-type="fig" rid="F1">Figure 1</xref>). In addition, the concentration of TBARS in erythrocytes in patients with nephrolithiasis (before URSL and after URSL) differed markedly from healthy volunteers (<xref ref-type="fig" rid="F2">Figure 2</xref>). The TBARS content in erythrocytes in patients with nephrolithiasis (before URSL and after URSL) was significantly higher than in controls [and increase &#x2013; about 25% (before URSL), and about 35% (after URSL)] (<xref ref-type="fig" rid="F2">Figure 2</xref>). The level of TBARS in erythrocytes from patients after URSL was also changed, compared with patients before URSL, however, it was not statistically significant (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>The level of TBARS in plasma in patients with nephrolithiasis (before and after URSL), and in control plasma obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g001.tif"/>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>The level of TBARS in erythrocytes in patients with nephrolithiasis (before and after URSL), and in control erythrocytes obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g002.tif"/>
</fig>
<p>Other experiments showed that the concentration of isoprostane in urine from patients (before and after URSL) was found to be higher than the concentration of isoprostane in urine obtained from healthy volunteers (<xref ref-type="fig" rid="F3">Figure 3</xref>). The concentration of isoprostane in urine from patients (after URSL) was also higher than in patients (before URSL) (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>The level of 8-isoPGF<sub>2&#x03B1;</sub> in urine in patients with nephrolithiasis (before and after URSL), and in control urine obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g003.tif"/>
</fig>
<p>The level of carbonyl groups in plasma proteins from patients with nephrolithiasis (before and after URSL) was found to be higher than the level of carbonyl groups in plasma proteins obtained from healthy volunteers (<xref ref-type="fig" rid="F4">Figure 4</xref>). On the other hand, the level of carbonyl groups in proteins from patients (after URSL) was lower than in proteins from patients (before URSL) (<xref ref-type="fig" rid="F4">Figure 4</xref>). However, this change (in the concentration of carbonyl groups) was not statistically significant (<xref ref-type="fig" rid="F4">Figure 4</xref>). <xref ref-type="fig" rid="F5">Figure 5</xref> demonstrates that the level of thiol groups in proteins from patients (after URSL) was slightly lower than in proteins from patients (before URSL), but not statistically significant.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>The level of carbonyl groups in plasma proteins in patients with nephrolithiasis (before and after URSL), and in control plasma proteins obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>The level of thiol groups in plasma proteins in patients with nephrolithiasis (before and after URSL), and in control plasma proteins obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g005.tif"/>
</fig>
<p><xref ref-type="fig" rid="F6">Figure 6</xref>&#x2013;<xref ref-type="fig" rid="F9">9</xref> demonstrate parameters of hemostasis in patients with nephrolithiasis before and after URSL. For example, blood platelet counts were (about 14%) lower in patients after URSL than in healthy subjects or in patients before URSL, but these changes were not statistically significant (<xref ref-type="fig" rid="F6">Figure 6</xref>). Neither, fibrinogen, D-dimer and coagulation times (APTT, PT, and TT) were influenced by the presence of nephrolithiasis, nor by treatment with URSL (<xref ref-type="fig" rid="F7">Figure 7</xref>&#x2013;<xref ref-type="fig" rid="F9">9</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p>The level of blood platelets in patients with nephrolithiasis (before and after URSL), and in from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g006.tif"/>
</fig>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption><p>The level of fibrinogen in plasma from patients with nephrolithiasis (before and after URSL), and in control plasma obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g007.tif"/>
</fig>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption><p>The level of D-dimer in plasma in patients with nephrolithiasis (before and after URSL), and in control plasma obtained from healthy volunteers. Results are means &#x00B1; SD. The statistically analysis was done by Mann&#x2013;Whitney test (for means &#x00B1; SD).</p></caption>
<graphic xlink:href="fphys-10-00799-g008.tif"/>
</fig>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption><p>The activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) of plasma in patients with nephrolithiasis (before and after URSL), and in control plasma obtained from healthy volunteers. Results are given as means &#x00B1; SD. The statistical analysis was performed using the Mann&#x2013;Whitney test (for all times: <italic>p</italic> &#x003E; 0.05 &#x2013; patients [(before/after URSL] <italic>versus</italic> healthy subjects; <italic>p</italic> &#x003E; 0.05 patients [after ESWL] <italic>versus</italic> patients [(before URSL]).</p></caption>
<graphic xlink:href="fphys-10-00799-g009.tif"/>
</fig>
<p>Moreover, we did not observe the difference in concentrations of biomarkers of oxidative stress between the group of men and the group of women.</p>
</sec>
<sec><title>Discussion</title>
<p>Lipids and proteins are major targets for oxidants. Oxidative stress itself is known to play a role in nephrolithiasis through the action of free radicals, which are believed to initiate the inflammation process and induce renal cellular injury (<xref ref-type="bibr" rid="B11">Khan, 2005</xref>, <xref ref-type="bibr" rid="B12">2012</xref>, <xref ref-type="bibr" rid="B13">2013a</xref>,<xref ref-type="bibr" rid="B14">b</xref>, <xref ref-type="bibr" rid="B15">2014</xref>; <xref ref-type="bibr" rid="B4">Boonla et al., 2007</xref>; <xref ref-type="bibr" rid="B17">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="B5">Ceban et al., 2016</xref>). In addition, increased oxidative stress may also be correlated with kidney stone development (<xref ref-type="bibr" rid="B7">Gaspar et al., 2010</xref>). For example, oxidative stress has been reported in the erythrocytes of patients with calcium oxalate stones, resulting in renal tubular damage and increases in stone size (<xref ref-type="bibr" rid="B17">Ma et al., 2014</xref>). Other studies suggest that urinary levels of oxalate and citric oxide may be correlated with lipid peroxidation (<xref ref-type="bibr" rid="B9">Huang et al., 2003</xref>). The present study by using different biomarkers of oxidative stress &#x2013; damages of lipids, including the change of TBARS (in plasma and erythrocytes) and the change of isoprostane level in urine provides evidence that in patients with nephrolithiasis, oxidative stress &#x2013; lipid peroxidation occurs. It should be underlined that in our present experiments tested samples from patients were taken before and after URSL. It is very important, because various drugs, which are used during treatment (i.e., surgery) may induce oxidative stress in different tissues, blood cells and plasma (<xref ref-type="bibr" rid="B23">Wang et al., 2017</xref>). However, <xref ref-type="bibr" rid="B5">Ceban et al. (2016)</xref> studied oxidant and antioxidant status in the blood of patients with complicated urolithiasis pre- and post-surgery. Oxidant and antioxidant status was measured also by various parameters, including the level of thiol groups and activity of different antioxidant enzymes (i.e., glutathione dismutase and glutathione reductase). Experiments of these authors demonstrated that the surgical treatment of complicated urolithiasis leads a decrease of the oxidative stress and an increase in potential of antioxidant status. On the other hand, <italic>in vitro</italic> and <italic>in vivo</italic> experiments show that increased oxidative stress is associated with kidney stone development (<xref ref-type="bibr" rid="B11">Khan, 2005</xref>, <xref ref-type="bibr" rid="B12">2012</xref>, <xref ref-type="bibr" rid="B13">2013a</xref>,<xref ref-type="bibr" rid="B14">b</xref>, <xref ref-type="bibr" rid="B15">2014</xref>; <xref ref-type="bibr" rid="B4">Boonla et al., 2007</xref>; <xref ref-type="bibr" rid="B17">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="B5">Ceban et al., 2016</xref>). Our earlier results indicate that ESWL also induces the oxidative stress (measured by the level of carbonyl groups in plasma proteins in patients with nephrolithiasis) and modulates hemostasis in these patients (<xref ref-type="bibr" rid="B24">Wozniak et al., 2017</xref>). A key novel finding of this experiment is that patients with nephrolithiasis undergoing other method for treatment &#x2013; URSL, experience an increase in lipid peroxidation (measured by two typical biomarkers: TBARS and isoprostanes), as compared to healthy volunteers. Moreover, changes in lipid peroxidation were found between patients before URSL and patients who had completed treatment.</p>
<p>Hemostasis is thought to be modulated by oxidative stress (<xref ref-type="bibr" rid="B18">Nowak et al., 2010</xref>). However, in the present study, no changes in oxidative damage to plasma proteins, indicated by the levels of thiol groups and carbonyl groups, were observed in the nephrolithiasis patients before URSL and after URSL. In addition, a significant novel finding is that URSL does not appear to induce changes in hemostasis, measured by various typical parameters, including blood platelet count, fibrinogen concentration and coagulation times in these patients. The only possible explanation for this lack of observed change was that no oxidative damage had occurred to the plasma proteins. <xref ref-type="bibr" rid="B10">Hughes et al. (2015)</xref> also report that treatment of solitary kidney stones by SWL does not appear to influence the biochemical parameters of hemostasis, measured by coagulation times (APTT and PT).</p>
<p>This present study is the first to examine the effect of URSL on parameters of oxidative stress and hemostasis in patients with nephrolithiasis. Our findings indicate that URSL does not induce any oxidative modification in plasma proteins nor does it change the hemostatic parameters in these patients. However, the differences in levels of oxidative stress biomarkers are small, but they are statistically significant. Moreover, it is not clear whether these statistical changes are clinically significant. Therefore, further experiments based on larger groups of patients are needed to more precisely determine its influence on oxidative stress and hemostasis.</p>
</sec>
<sec><title>Data Availability</title>
<p>The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.</p>
</sec>
<sec><title>Ethics Statement</title>
<p>The protocol was passed by the Committee for Research on Human Subjects of the Medical University of &#x0141;&#x00F3;d&#x017A; RNN/101/13/KE. The first, participants provided verbal consent to the researchers, and later participants provided written the documents. Authors had access to identifying participant information.</p>
</sec>
<sec><title>Author Contributions</title>
<p>All authors have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by grant B1711000000044.01 from the University of &#x0141;&#x00F3;d&#x017A;.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname> <given-names>Y.</given-names></name> <name><surname>Steiner</surname> <given-names>M.</given-names></name></person-group> (<year>1973a</year>). <article-title>Sulphydryl and disulphide groups of platelet membranes: determination of disulphide groups.</article-title> <source><italic>Biochim. Biophys. Acta</italic></source> <volume>311</volume> <fpage>26</fpage>&#x2013;<lpage>37</lpage>.</citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname> <given-names>Y.</given-names></name> <name><surname>Steiner</surname> <given-names>M.</given-names></name></person-group> (<year>1973b</year>). <article-title>Sulphydryl and disulphide groups of platelet membranes: determination of sulphydryl groups.</article-title> <source><italic>Biochim. Biophys. Acta</italic></source> <volume>311</volume> <fpage>38</fpage>&#x2013;<lpage>44</lpage>.</citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartosz</surname> <given-names>G.</given-names></name></person-group> (<year>2008</year>). <source><italic>Druga twarz tlenu.</italic></source> <publisher-loc>Warszawa</publisher-loc>: <publisher-name>PWN</publisher-name>. <volume>7</volume> <fpage>99</fpage>&#x2013;<lpage>120</lpage>.</citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boonla</surname> <given-names>C.</given-names></name> <name><surname>Wunsuwan</surname> <given-names>R.</given-names></name> <name><surname>Tungsanga</surname> <given-names>K.</given-names></name> <name><surname>Tosukhowong</surname> <given-names>P.</given-names></name></person-group> (<year>2007</year>). <article-title>Urinary 8-hydroxydeoxyguanosie is elevated in patients with nephrolithiasis.</article-title> <source><italic>Urol. Res.</italic></source> <volume>35</volume> <fpage>185</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1007/s00240-007-0098-0</pub-id> <pub-id pub-id-type="pmid">17541572</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ceban</surname> <given-names>E.</given-names></name> <name><surname>Banov</surname> <given-names>P.</given-names></name> <name><surname>Galescu</surname> <given-names>A.</given-names></name> <name><surname>Botnari</surname> <given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Oxidative stress and antioxidant status in patients with complicated urolithiasis.</article-title> <source><italic>J. Med. Life</italic></source> <volume>9</volume> <fpage>259</fpage>&#x2013;<lpage>262</lpage>. <pub-id pub-id-type="pmid">27974930</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garca</surname> <given-names>M. F.</given-names></name> <name><surname>Kavak</surname> <given-names>S.</given-names></name> <name><surname>Gecit</surname> <given-names>I.</given-names></name> <name><surname>Meral</surname> <given-names>I.</given-names></name> <name><surname>Demir</surname> <given-names>H.</given-names></name> <name><surname>Turan</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Effects of shock waves on oxidative stress in parotid gland of rat.</article-title> <source><italic>Toxicol. Ind. Health</italic></source> <volume>30</volume> <fpage>454</fpage>&#x2013;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1177/0748233712457452</pub-id> <pub-id pub-id-type="pmid">22933554</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname> <given-names>S.</given-names></name> <name><surname>Niculite</surname> <given-names>C.</given-names></name> <name><surname>Cucu</surname> <given-names>D.</given-names></name> <name><surname>Marcu</surname> <given-names>I.</given-names></name></person-group> (<year>2010</year>). <article-title>Effect of calcium oxalate on renal cells as revealed by real-time measurement of extracellular oxidative burst.</article-title> <source><italic>Biosens. Bioelectron.</italic></source> <volume>25</volume> <fpage>1729</fpage>&#x2013;<lpage>1734</lpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2009.12.013</pub-id> <pub-id pub-id-type="pmid">20047824</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gecit</surname> <given-names>I.</given-names></name> <name><surname>Kavak</surname> <given-names>S.</given-names></name> <name><surname>Meral</surname> <given-names>I.</given-names></name> <name><surname>Demir</surname> <given-names>H.</given-names></name> <name><surname>Ceylan</surname> <given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Effects of shock waves on oxidative stress and some tace element levels of rat liver and diaphragm muscles.</article-title> <source><italic>Cell Biochem. Funct.</italic></source> <volume>30</volume> <fpage>303</fpage>&#x2013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1002/cbf.2802</pub-id> <pub-id pub-id-type="pmid">22247008</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>H. S.</given-names></name> <name><surname>Ma</surname> <given-names>M. C.</given-names></name> <name><surname>Chen</surname> <given-names>C. F.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones.</article-title> <source><italic>Urology</italic></source> <volume>62</volume> <fpage>1123</fpage>&#x2013;<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1016/s0090-4295(03)00764-7</pub-id> <pub-id pub-id-type="pmid">14665375</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname> <given-names>S. F.</given-names></name> <name><surname>Thomas-Wright</surname> <given-names>S. J.</given-names></name> <name><surname>Banwell</surname> <given-names>J.</given-names></name> <name><surname>Williams</surname> <given-names>R.</given-names></name> <name><surname>Moyes</surname> <given-names>A. J.</given-names></name> <name><surname>Mushtaq</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A pilot study to evaluate haemostatic function, following shock wave lithiotripsy (SWL) for the treatment of solitary kidney stones.</article-title> <source><italic>PLoS One</italic></source> <volume>10</volume>:<issue>e0125840</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0125840</pub-id> <pub-id pub-id-type="pmid">25938233</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>S. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Hyperoxaluria-induced oxidative stress and antioxidants for renal protection.</article-title> <source><italic>Urol. Res.</italic></source> <volume>33</volume> <fpage>349</fpage>&#x2013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1007/s00240-005-0492-4</pub-id> <pub-id pub-id-type="pmid">16292585</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>S. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?</article-title> <source><italic>Urol. Res.</italic></source> <volume>40</volume> <fpage>95</fpage>&#x2013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1007/s00240-011-0448-9</pub-id> <pub-id pub-id-type="pmid">22213019</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>S. R.</given-names></name></person-group> (<year>2013a</year>). <article-title>Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations.</article-title> <source><italic>J. Urol.</italic></source> <volume>189</volume> <fpage>803</fpage>&#x2013;<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2012.05.078</pub-id> <pub-id pub-id-type="pmid">23022011</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>S. R.</given-names></name></person-group> (<year>2013b</year>). <article-title>Stress oxidative: nephrolithiasis and chronic kidney diseases.</article-title> <source><italic>Minerva Med.</italic></source> <volume>104</volume> <fpage>23</fpage>&#x2013;<lpage>30</lpage>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>S. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis.</article-title> <source><italic>Transl. Androl. Urol.</italic></source> <volume>3</volume> <fpage>256</fpage>&#x2013;<lpage>276</lpage>.</citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname> <given-names>R. L.</given-names></name> <name><surname>Garland</surname> <given-names>D.</given-names></name> <name><surname>Oliver</surname> <given-names>C. N.</given-names></name> <name><surname>Amici</surname> <given-names>A.</given-names></name> <name><surname>Climent</surname> <given-names>I.</given-names></name> <name><surname>Lenz</surname> <given-names>A. G.</given-names></name><etal/></person-group> (<year>1990</year>). <article-title>Determination of carbonyl content in oxidatively modified proteins.</article-title> <source><italic>Methods Enzymol.</italic></source> <volume>186</volume> <fpage>464</fpage>&#x2013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/0076-6879(90)86141-h</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>M.-C.</given-names></name> <name><surname>Chen</surname> <given-names>Y.-S.</given-names></name> <name><surname>Huang</surname> <given-names>H.-S.</given-names></name></person-group> (<year>2014</year>). <article-title>Erythrocyte oxidative stress in patients with calcium oxalate stones correlates with stone size and renal tubular damage.</article-title> <source><italic>Urology</italic></source> <volume>8</volume> <fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.urology.2013.09.050</pub-id> <pub-id pub-id-type="pmid">24360074</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname> <given-names>P.</given-names></name> <name><surname>Olas</surname> <given-names>B.</given-names></name> <name><surname>Wachowicz</surname> <given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>Oxidative stress in haemostasis.</article-title> <source><italic>Postepy Biochem.</italic></source> <volume>56</volume> <fpage>239</fpage>&#x2013;<lpage>247</lpage>.</citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nuttall</surname> <given-names>M. C.</given-names></name> <name><surname>Abbaraju</surname> <given-names>J.</given-names></name> <name><surname>Dickinson</surname> <given-names>I. K.</given-names></name> <name><surname>Sriprasad</surname> <given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>A review of studies reporting on complications of upper urinary tract stone ablation using the holmium: YAG laser.</article-title> <source><italic>Br. J. Med. Surg. Urol.</italic></source> <volume>3</volume> <fpage>151</fpage>&#x2013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjmsu.2010.01.008</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seitz</surname> <given-names>C.</given-names></name> <name><surname>Tanovic</surname> <given-names>E.</given-names></name> <name><surname>Kikic</surname> <given-names>Z.</given-names></name> <name><surname>Fajkovic</surname> <given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>Impact of stone size, locatiom, composition, impaction, and hydronephrosis on the efficacy of holmium: YAG-laser ureterolithotripsy.</article-title> <source><italic>Eur. Urol.</italic></source> <volume>52</volume> <fpage>1751</fpage>&#x2013;<lpage>1757</lpage>.</citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>W.</given-names></name> <name><surname>Cai</surname> <given-names>C. J.</given-names></name> <name><surname>Sun</surname> <given-names>C. Y.</given-names></name> <name><surname>Xue</surname> <given-names>B. X.</given-names></name> <name><surname>Shan</surname> <given-names>Y. X.</given-names></name></person-group> (<year>2015</year>). <article-title>Subcapsular renal hematoma after ureteroscopy with holmium:yttrium-aluminum-garnet laser lithotripsy.</article-title> <source><italic>Lasers Med. Sci.</italic></source> <volume>30</volume> <fpage>1527</fpage>&#x2013;<lpage>1532</lpage>. <pub-id pub-id-type="doi">10.1007/s10103-015-1760-3</pub-id> <pub-id pub-id-type="pmid">25943289</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wachowicz</surname> <given-names>B.</given-names></name></person-group> (<year>1984</year>). <article-title>Adenine nucleotides in thrombocytes of birds.</article-title> <source><italic>Cell. Biochem. Funct.</italic></source> <volume>2</volume> <fpage>167</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1002/cbf.290020310</pub-id> <pub-id pub-id-type="pmid">6478540</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Zhong</surname> <given-names>B.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Hou</surname> <given-names>P.</given-names></name> <name><surname>Meng</surname> <given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Comparison of the efficacy and safety of URSL, RPLU, and MPCNL for treatment of large upper impacted ureteral stones: a randomized controlled trial.</article-title> <source><italic>BMC Urol.</italic></source> <volume>17</volume>:<issue>50</issue>. <pub-id pub-id-type="doi">10.1186/s12894-017-0236-0</pub-id> <pub-id pub-id-type="pmid">28662708</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname> <given-names>P.</given-names></name> <name><surname>Kontek</surname> <given-names>B.</given-names></name> <name><surname>R&#x00F3;&#x017C;a&#x0144;ski</surname> <given-names>W.</given-names></name> <name><surname>Olas</surname> <given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Evaluation of hemostasis parameters and the role of the oxidative damage to plasma proteins in the modulation of hemostasis in patients with nephrolithiasis before and after extracorporeal shock wave lithotripsy.</article-title> <source><italic>PLoS One</italic></source> <volume>10</volume>:<issue>e0185157</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0185157</pub-id> <pub-id pub-id-type="pmid">28968428</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname> <given-names>P.</given-names></name> <name><surname>Kontek</surname> <given-names>B.</given-names></name> <name><surname>R&#x00F3;&#x017C;a&#x0144;ski</surname> <given-names>W.</given-names></name> <name><surname>Olas</surname> <given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>The lipid peroxidation in patients with nephrolithiasis before and after extracorporeal shock wave lithotripsy.</article-title> <source><italic>Future Med. Chem.</italic></source> <volume>10</volume> <fpage>2685</fpage>&#x2013;<lpage>2693</lpage>. <pub-id pub-id-type="doi">10.4155/fmc-2018-0149</pub-id> <pub-id pub-id-type="pmid">30518231</pub-id></citation></ref>
</ref-list>
</back>
</article>